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Abstract  
AIM: To rule out maternal and pregnancy factors that may contribute to platelet count (PLT) 
changes in the first trimester of gestation and examine if there is any association between its levels 
and adverse perinatal outcome.  
METHODS: The study population included all patients from the first-trimester visit between 2013-
2015 with pregnancy results. Linear multiple regression was constructed to rule out variables that 
may have a significant contribution to PLT. For each adverse outcome at birth, multiple logistic 
regression analysis was implemented to estimate the PLT effect. 
 
RESULTS: PLT was measured in 6092 patients. There was the significant contribution on PLT in 
the first trimester from maternal weight, the presence of rheumatologic disease, BHCG levels and 
MPV. There was a significant association between PLT and abnormal cardiotocography at delivery 
(OR 1.004; IC95% 1.001 to 1.007) and C-Section due to abnormal CTG (OR 1.005; IC95% 1.002 to 
1.008). When adjusted for factors that interact with PLT there was also a significant association with 
pH at birth < 7.10 and gestational diabetes. 
 
CONCLUSIONS: Maternal and pregnancy factors can poorly predict relevant changes in PLT at the 
first trimester of gestation. PLT at first trimester of pregnancy might predict adverse perinatal 
outcome in combination with other markers.
 
 
 
 
 
Introduction 
 
Prediction of perinatal outcome from early 
stages of pregnancy has become a priority and a line 
of research in the last decades as a way to improve 
both maternal and neonatal healthcare. Several 
methods of screening have been implemented using 
maternal characteristics and obstetric history, 
biophysical and biochemical tests under the 
assumption that this may enhance obstetrical results 
through pharmacological intervention and a closer 
follow-up [1, 2].  
Normal pregnancy is characterised by an 
increase in platelet aggregation and a slight decrease 
in the mean platelet count than in healthy non-
pregnant women [3-5]. This can be of no significance 
or clinical importance and may be due to increased 
PLT turnover, immune-related mechanisms, plasma 
dilution, or a complication of a more severe underlying 
gestational disorder. Moreover, histological 
examination of the human placenta revealed that 
during first stages of maternal pregnancy platelets are 
trapped by endovascular trophoblast aggregates that 
are formed inside the spiral arteries [6]. 
Platelets are likely to be activated and release 
several soluble factors, promoting the invasive 
capacity of extravillous trophoblasts. Hence, maternal 
platelets might be a candidate that attracts extravillous 
trophoblasts into the spiral arteries and encourages 
maternal vascular remodelling during early 
placentation process [7].
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  28                                                                                                                                                                                                                       http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
Mild decreases in platelet count occur in 
about 3 to 5 % of pregnant women (gestational 
thrombocytopenia, incidental thrombocytopenia). 
Gestational thrombocytopenia is characterised by mild 
asymptomatic low platelet count in a patient without 
any history of such condition and most frequently 
during the third trimester. It is not associated with 
maternal or neonatal sequelae and spontaneously 
resolves after delivery [8, 9]. Platelet counts are 
typical > 75,000/μL, with about two-thirds being 
130,000 to 150,000/μL. 
Longitudinal studies showed that in women 
with the adverse perinatal outcomes such as 
Preeclampsia (PE) and intrauterine growth restriction 
(IUGR) there is a reduction in platelet count and this 
may predate their development by 3 to 5 weeks [10].  
Some others showed that hypertensive 
disorders cannot be predicted based on platelet count 
during early stages of pregnancy. Nevertheless, an 
increased mean platelet volume (MPV) reflects 
enhanced platelet activation which may be caused by 
impairment in uteroplacental circulation. When MPV of 
10.1 fL or more is used as a threshold, the 
pregnancies that are destined to develop IUGR and 
PE can be predicted with considerably high sensitivity 
and specificity combined with other biochemical 
markers such as low PAPPA [11,12].
 
Several reports investigating changes in PLT 
number, function and MPV indicate increased PLT 
turnover following activation within the maternal 
vasculature in impaired placentation conditions such 
as preeclampsia [13]. 
The main goal of our research is trying to 
understand PLT changes in the first trimester of 
gestation and its relation to pregnancy outcome in an 
era when sophisticated tests using biochemical or 
genetic markers are developed. We consider that 
there might be a place for the simple blood test that 
can be performed for the identification of women at 
stake of presenting gestational complications and then 
be sent to more complex surveillance. 
 
 
Material and Methods 
 
A retrospective population-based study was 
performed between 2013 and 2015 to examine 
whether platelet levels in the first trimester of 
pregnancy, 8-14 weeks of gestation, are associated 
with obstetric complications. The second aim is to rule 
out variables that may have a significant contribution 
on platelet levels during the first trimester. 
 
Maternal and obstetrical characteristics were 
collected for patients attending the first-trimester 
clinic.We assessed the following perinatal outcomes: 
fetal gender, birth weight, gestational age at birth, bad 
perinatal outcome defined as: preeclampsia (PE), 
intrauterine growth retardation as birthweight below 
the 10
th
 centile (IUGR), perinatal/antenatal death, non-
reassuring cardiotocography (CTG), cesarean section 
(CS) due to non-reassuring CTG, spontaneous 
delivery before 37 weeks of gestation, Ph at birth       
< 7.10, newborn resuscitation > 3, Apgar score at 5 
min ≤ 7. 
Blood samples were obtained by antecubital 
venepuncture between 8 to 14 weeks of gestation 
before the clinical visit for routine blood test 
assessment. Platelet count was measured by an 
automated hematologic analyser.
 
Regarding the statistical analysis, values were 
reported as percentages or means and standard 
deviations
 
or, for non-normal distributions, as medians
 
and interquartile ranges (IQRs). 
Differences of means between two groups 
were calculated by the Student’s t-test for 
independent samples if the normal distribution could 
be assumed. In the Student's t-test for independent 
samples, we used the Levene's test for homogeneity 
of variances. If normality was not valid, we used the 
nonparametric Mann–Whitney U-test. Differences of 
more than two means between groups were 
calculated by the ANOVA test if the normal distribution 
could be assumed or by the nonparametric Kruskal–
Wallis test if normality was not valid. The Scheffé test 
was used for multiple comparisons of means. We 
firstly performed a simple linear regression with 15 
different variables that might have a significant 
contribution to the platelet count in the first trimester of 
pregnancy selected by authors criteria. Ten of the 
above mentioned fifteen variables were used in the 
multivariate analysis. 
 
The relation between platelets count as the 
predictor and a bad perinatal outcome was analysed 
firstly by simple logistic multiple regression. For each 
adverse outcome at birth, a multiple logistic 
regression analysis was implemented to estimate the 
platelets levels effect. All tests were two-tailed. P-
values below 0.05 were considered statistically 
significant. Statistical analysis was performed using 
the SPSS version 18 (SPSS Inc, Chicago, IL, USA). 
The present study was approved by the 
Ethical Committee of Hospital General Universitario 
Gregorio Marañon de Madrid (Comité ético de 
Investigacion clínica, reference number 
OBS05042016, date of approval 05.04.2016). 
 
 
Results 
Platelet count was measured in 6092 patients 
in the first trimester of pregnancy. The distribution did 
not follow a normal pattern in our sample (Figure 1); of 
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these, 22 had thrombocytopenia (0.36%) with PLT 
below 50,000/μL.  
 
Figure 1: PLT distribution in the first trimester of pregnancy
 
 
Predictive linear multivariate regression 
analysis of platelet count in the first trimester of 
gestation resulted in a significant model (Table 1, p < 
0.001) with an explanatory capacity of 28% (Adjusted 
R-squared = 0.28). 
Table 1: Linear multivariate regression analysis of PLT at first 
trimester of pregnancy  
 
 
Coefficient
 
95% CI 
p-value 
Upper Lower 
Rheumatological disease Yes/No -17.941 -26.290 -9.591 <0.001 
BHCG (Mom) -2.208 -4.170 -246 0.027 
MPV (fL) -25.462 -27.015 -23.910 <0.001 
Maternal weight (kg) 324 194 454 <0.001 
 
From the total population, 1129 pregnancies 
(26.8%; IC95% 25.5 to 28.0%) were complicated by 
any of the following adverse perinatal outcomes as 
summarised in Table 2. The most frequent ones were 
abnormal CTG in labour (7.2%; IC95% 6.4 to 7.9%) 
and IUGR (7.1%; IC95% 6.3 to 7.8%).
 
Table 2: Perinatal adverse outcomes 
 
 
Total 
(N) 
Absolute 
frequency 
(n) 
              Relative frequency 
(%) 
95% CI 
lower upper 
Preeclampsia 4223 81 1.9 1.5 2.3 
Perinatal/antenatal death 4223 15 0.4 0.2 0.5 
Abnormal CTG 4223 302 7.2 6.4 7.9 
CS due to abnormal CTG 4223 250 5.9 5.2 6.6 
IUGR  4223 298 7.1 6.3 7.8 
Preterm birth < 37 sem 4221 125 3.0 2.4 3.5 
Ph < 7.10 4220 95 2.3 1.8 2.7 
Resuscitation > 3 4222 293 6.9 6.2 7.7 
Apgar at 5 min ≤ 7 4221 54 1.3 0.9 1.6 
Gestational diabetes 4231 239 5.6 5.0 6.3 
Any adverse outcome 4243 1139 26.8 25.5 28.0 
 
 
According to simple binary logistic regression, 
there was a significant association between platelets 
levels in the first trimester (1000/μL) as the predictor 
and the following adverse outcomes as seen in Table 
3.
 
Table 3: Simple logistic binary regression (predictor PLT 
1000//μL) 
Adverse perinatal outcome 
OR 
95% CI 
p-value 
lower  Upper 
Preeclampsia 1.002 0.997 1.007 0.470 
Perinatal/antenatal death 1.007 0.997 1.017 0.165 
Abnormal CTG 1.004 1.001 1.007 0.003 
CS due to abnormal CTG 1.005 1.002 1.008 0.001 
IUGR 1.000 0.997 1.003 0.918 
Preterm birth < 37 sem 1.001 0.997 1.005 0.634 
Ph < 7.10 1.000 0.996 1.005 0.963 
Resuscitation > 3 1.002 0.999 1.005 0.144 
Apgar at 5 min ≤ 7 1.005 0.999 1.010 0.101 
Gestational diabetes 1.002 0.999 1.005 0.197 
Any adverse outcome 1.002 1.000 1.003 0.040 
 
For each adverse outcome, a multiple logistic 
binary regression models was constructed and 
adjusted by rheumatologic disease. BHCG levels, 
MPV and maternal weight taking into account their 
interaction with platelets count. 
The adjusted effect from PLT resulted into a 
significant contribution to the following outcomes 
(Table 4):
 
Table 4: Estimative model adjusted by interaction factors 
Adverse perinatal 
outcome 
OR 
95% CI 
p-value 
upper lower 
Preeclampsia 1.002 0.997 1.007 0.470 
Perinatal/antenatal 
death 
1.007 0.997 1.017 0.165 
Abnormal CTG 
0.988 x 
1.00025
weight
 
0.975 x 
1.00004
weight
 
1.001 x 
1.00045
weight
 
0.018 
CS due to abnormal 
CTG 
0.986 x 1.0003
weight
 
0.972 x 
1.0001
weight
 
0.999 x 
1.0005
weight
 
0.007 
IUGR 1.000 0.997 1.003 0.918 
Preterm birth < 37 sem 1.001 0.997 1.005 0.634 
Ph < 7.10 1.010 x 0.988
BHCG
 
1.002 x 
0.982
BHCG
 
1.017 x 
0.994
BHCG
 
0.009 
Resuscitation > 3 1.002 0.999 1.005 0.144 
Apgar at 5 min ≤ 7 1.005 0.999 1.010 0.101 
Gestational diabetes 
1.007 x 0.998
MPV
 x 
1.0002
weight
 
0.983 x 0.995
MPV
 
x 1.00004
weight
 
1.032 x 
0.99995
MPV
 
x 1.00042
weight
 
0.019 
Any adverse outcome 0.987 x 1.0002
weight
 
0.978 x 
1.0001
weight
 
0.995 x 
1.0004
weight
 
0.002 
 
Abnormal CTG: The adjusted effect by 
platelets was significant (p=0.018) and had interaction 
with maternal weight as seen in this example:  
0.988 x 1.00025
60
 = 0.988 x 1.015 = 1.0029 
The risk of a non-reassuring CTG was raised 
by 0.29% for every increase by 1000 platelets/μL in a 
60 kg pregnant woman 
CS due to abnormal CTG: The adjusted effect 
by platelets was significant (p=0.007) and had 
interaction with maternal weight as seen below: 
0.986 x 1.0003
60
 = 0.986 x 1.015 = 1.0009 
The risk of CS due to abnormal CTG was raised 
0.09% for every increase of 1000 platelets/μL in a 60 
kg pregnant woman. 
Ph < 7.10: The adjusted effect by platelets 
was significant (p=0.09) and had interaction with 
BHCG Mom values as seen in the table. 
Gestational diabetes: The adjusted effect by 
platelets was significant (p=0.019) and had interaction 
with MPV values and maternal weight as seen in this 
example; 
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1.007 x 0.998
9
 x 1.0002
60
 = 1.007 x 0.982 x 1.012 = 1.0009 
In a 60 kg patient with an MPV of 9 fl in the 
first trimester, the risk to develop gestational diabetes 
is raised 0.09% per every increase by 1000 
platelets/μL. 
 
 
Discussion 
 
A relevant finding of our study is that the PLT 
in the first trimester of pregnancy is not associated 
with PE. IUGR or preterm delivery. A significant 
association was found between abnormal CTG. CS 
due to abnormal CTG. And low pH at birth and 
gestational diabetes when adjusted for interaction 
factors and an increase in PLT. This association 
remains very mild, and its significance could be 
noticed as a result of a very large sample of patients. 
We also hypothesised that patients with worse 
outcome at birth and late stage of pregnancy could 
show higher PLT values despite the BHCG increment 
between 8 to 11 weeks as a consequence of an 
unclear dysregulation in the inflammatory process that 
occurs during early placentation. However, its clinical 
importance seems weak further research combining 
simple markers such as MPV or PAPPA could 
potentially improve PLT predicting value. 
 
Even though some of the reports did not find 
an association between low PLT in pregnancy and 
hypertensive disorders or increase in the perinatal 
morbidity and mortality. The same show significantly 
higher rates of preterm birth before 37 weeks of 
gestation (OR 1.82, 1.1-2.97, 95% CI) were 
documented among patients with platelets < 
100.000/μL [14]. 
PE and IUGR are thought to be the 
consequence of impaired placentation due to an 
inadequate trophoblastic invasion of the spiral 
arteries. An imbalance between angiogenic and anti-
angiogenic proteins [15. 16] and endothelial damage 
in which platelets may play a role in its pathogenesis 
[17]. 
Discordant conclusions have been published 
regarding platelet number and size variations in 
normal and complicated pregnancies. Some research 
groups found no difference in platelet counts and MPV 
values between complicated and controls, whereas 
others [18] demonstrated lower platelets and higher 
MPV in women suffering from PE. However, it seems 
that early pathogenesis of placental impairment 
disease during the first weeks of gestation does not 
have a clear influence on platelet count.  
The vascular remodelling that ensures 
appropriate placental perfusion is an important 
component of human reproduction and should be 
secured by several complementary mechanisms. In 
this respect, promotion of trophoblast invasion by 
maternal platelets could be one of the multiple 
mechanisms that regulate this vascular remodelling. 
Although the vascular changes might occur in the 
absence of maternal platelets.
 
The fact that pregnancies with severe platelet 
defects can achieve an uneventful pregnancy may 
suggest that maternal platelets are not a fundamental 
element of human placentation. 
The objective of finding a clinically useful first-
trimester screening for pregnancy complications is the 
identification of pregnancies at high-risk of developing 
gestational and perinatal adverse outcome and 
through pharmacological intervention and a closer 
follow-up in this high-risk group reduces the 
prevalence of the disease or diminishes its deleterious 
effects [19, 20, 21]. 
Severe thrombocytopenia with platelet count 
< 50.000/μL occurs in less than 5 % of preeclamptic 
women when the disease is established. However, the 
frequency and severity of thrombocytopenia increase 
with the severity of PE. and much more increased in 
patients with HELLP syndrome or those with 
eclampsia in whom disseminated intravascular 
coagulation may be a contributing factor [22]. Our 
research cannot identify or predict patients at risk of 
developing such problems and presumably not the 
ones that will have a poorer prognosis once any of 
these conditions are settled either, but further 
investigation should question this hypothesis. 
The other aim of the study was a method to 
design a model to predict changes in platelet count in 
the first trimester by maternal and obstetrical 
characteristics. Laboratory and ultrasound variables 
using linear multiple regression shows a mild capacity 
in explaining platelets variability. Only four variables 
demonstrated a significant contribution to PLT in the 
first trimester, but it helped us to understand more 
precisely what are some of the factors that explicate 
its variations during early stages of pregnancy  
Thrombocytopenia is very common in 
pregnant women. Evaluation of blood count has 
shown that thrombocytopenia is the second most 
common haematological problem in gestation. It may 
result from diverse aetiologies, but so far a method to 
predict and quantify platelet count changes at early 
stages of pregnancy has not been demonstrated. 
 
Platelet count is lower in pregnant compared 
to healthy non-pregnant women. It is believed that 
immunological mechanisms at the time of placentation 
are involved in the process [23]. However, the major 
factors that change the PLT in pregnancy are still to 
be specified. Our analysis only included the presence 
of rheumatologic conditions as the immunological 
factor, but its contribution resembles weak.
 
We also know that in pregnancy the demands 
on the hemostatic and fibrinolytic systems change to 
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prevent exceeding placental haemorrhage throughout 
gestation and especially during placental separation at 
delivery. A relative hypercoagulable state compared 
with non-pregnant women is caused by the marked 
increase in coagulation factors, reduced fibrinolysis, 
and increased platelet activity. 
BHCG is secreted by trophoblast. A layer of 
cells on the outside of the blastocyst that provides the 
embryo with nutrients and later forms part of the 
placenta and the fetal membranes. Extravillous 
cytotrophoblast produces hyperglycosylated hCG 
(hCG-H). The main form of BHCG present during the 
first two postconception weeks when implantation is 
taking place. hCG-H appears to promote invasion of 
extravillous cytotrophoblast into the myometrium wall 
to form gripping villi (interstitial invasion) and into the 
spiral arteries (endovascular invasion) to create a 
high-flow low-resistance vessels. 
 
During pregnancy, BHCG concentration 
peaks at 93.598 mIU/mL (range 27.300 to 233.000 
mIU/mL) at 8 to 11 weeks of gestation and as seen in 
our study this hormone is a significant contributor to 
PLT decrease maybe as a booster of platelet 
aggregation, activation, placental entrapment and 
hemodynamic changes (Figure 2). 
 
 
Figure 2: Relation between BHCG in Mom and PLT at first trimester 
of pregnancy 
 
It has long been known that platelet volume is 
a direct indicator of increased platelet synthesis and 
activation [24]. In normal pregnancies, a mild increase 
in platelet aggregation was observed, which is 
compensated by increased synthesis and 
consequently higher MPV values which are consistent 
with our findings.
 
Our study has several weaknesses. Despite 
the large sample size of women with platelet count 
measurement, only about one-third of them were 
eligible to take part as observations in our multiple 
regression works. Many of the variables that we took 
into account appeared to be irrelevant which 
necessitated looking for other ones that might be 
better predictors of platelet count changes in 
pregnancy. 
 
In conclusion, maternal and pregnancy factors 
can predict very mildly clinical relevant changes in 
PLT at the first trimester of gestation. PLT at first 
trimester of pregnancy might predict adverse perinatal 
outcome in combination with other markers, but its 
clinical use remains worthless as a unique test to 
choose. Further research should be undertaken to test 
for this purpose.
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